Torrent reported steady Q1FY22 results.
- Sales were up 3.8% YoY to Rs. 2134 crore
- EBITDA in Q1FY22 was at Rs. 677 crore, up 2% YoY with margins at 31.7%
- Consequent PAT was at Rs. 330 crore (up 2.8% YoY)
Key triggers for future price performance
- In India, Torrent is expected to increase specialty focus & new introductions to leverage patent expiry. Also, it forayed into fast growing trade generic segment for acute therapies
- Expects double digit growth in branded markets and high single digit in Germany
- Awaiting clearance for Dahej and Indrad facility from USFDA
For details, click on the link below: Link to the report
Shares of TORRENT PHARMACEUTICALS LTD. was last trading in BSE at Rs. 3069.7 as compared to the previous close of Rs. 3037.05. The total number of shares traded during the day was 28025 in over 872 trades.
The stock hit an intraday high of Rs. 3102.4 and intraday low of 3026.4. The net turnover during the day was Rs. 85072015.